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Comparison of clinico-pathological characteristics 
and survival of recurrent ovarian cancer patients on seven 
different chemo-protocols
Despite growing prevalence of ovarian cancer (OC) in 
 Pakistan, no literature evidence exists regarding its clinic-
-pathological characteristics, survival and compliance of 
patients with recurrent ovarian cancer on various chemo-
-protocols. An observational study was conducted by en-
rolling 251 recurrent OC patients on 7 different chemo-
-protocols, from a specialized cancer care hospital, Lahore, 
Pakistan, using convenient judgmental sampling. The 
study was conducted for a period of 6 months. Most of the 
patients were between 18 and 70 years of age, with IIIC 
FIGO stage and papillary serous histological grade. As per 
RECIST, improved partial response (PR) (63.3 %) and com-
plete response (CR) (52.1 %) was observed in the CP (carbo-
platin + paclitaxel) arm, substantiated by improved median 
progression free survival (PFS) and overall survival (OS) in 
CP and CD (carboplatin + docetaxel) arms, respectively, yet 
with no significant differences in survival curves, PFS (p = 
0.12) and OS (p = 0.22). Interestingly, the highest and the 
lowest patient non-compliance were observed in CG (car-
boplatin + gemcitabine) (81.6 %) and paclitaxel (4.5 %) arms, 
resp. As per the hazard model for survival, topotecan 
showed significant association with the therapy related 
events/deaths compared to other protocols. These data sug-
gest that CP regimen exhibited improved clinical efficacy 
and decreased toxicity related non-compliance in recurrent 
ovarian cancer patients of Lahore.
Keywords: ovarian cancer, carboplatin plus paclitaxel, topo-
tecan, bevacizumab, docetaxel
In women, ovarian cancer (OC) is the fourth most common cause of death and sixth 
most common type of cancer – making it a leading cause of mortality from all gyneco-
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40, is predominantly diagnosed in elderly postmenopausal women above 50 years of age 
(3). In routine clinical practice, OC diagnosis is made incidentally during the work-up of 
another clinical condition, while symptoms remain poorly defined with no definite indices 
to screen the asymptomatic women; however, if confined to ovaries, it is highly curable 
with improved five-year survival (4). Most patients are referred to the clinics with an ad-
vanced stage of disease – FIGO (International Federation of Gynecological Oncology) stage 
III and IV, requiring aggressive surgery and chemotherapy (5).
Over the last several years, carboplatin plus platinum based regimen has been the 
standard first line chemotherapy in ovarian cancer. However, despite 60–80 % response 
rate with carboplatin and paclitaxel, the majority of patients subsequently relapse and 
need further clinical management (3, 6). In this context, in previous years, numerous trials 
(GOG182, ICON5) have been conducted to add a third drug to the chemotherapeutic regi-
men in an attempt to increase overall survival (OS) (7). However, despite an increase in the 
number of therapies, the clinical judgment about treatment choices in recurrent cases has 
become even more complex. In this regard, the results of clinical trials and observational 
studies are becoming increasingly important in clinical decision making on managing the 
advanced stage disease.
Clinical management of ovarian cancer, just like other malignancies, has evolved 
from a single agent to a combination therapy. A number of studies have been conducted to 
compare several available chemotherapeutic options in an attempt to find an appropriate 
chemotherapeutic option for patients with recurrent disease (8, 9). Among the South Asian 
countries, ovarian cancer is reported to be higher in Pakistan (10, 11) and is the third most 
common malignancy in Pakistani women (12). Very few studies, prospective or observa-
tional, evaluated and compared clinical responses of seven available chemotherapeutic 
regimens used in the treatment of recurrent ovarian cancer patients. The present study is 
the first report that has compared the clinic-pathological characteristics, clinical responses, 
therapy compliance and toxicity of several chemo-therapeutic agents in recurrent ovarian 
cancer patients of Lahore, Pakistan.
EXPERIMENTAL
Ethical approval
The study was duly approved by the Ethical Committee of Clinical Research, Univer-
sity College of Pharmacy, University of the Punjab, Lahore, Pakistan, and the Hospital 
Committee of Ethics on Human Research of the Shaukat Khanum Memorial Cancer Hos-
pital & Research Center, Lahore, Pakistan.
Study design and population
The observational study was designed by enrolling a total of 251 recurrent ovarian 
cancer patients from Lahore, Pakistan. The study period was six months, from August 2015 
to January 2016, in a specialized cancer care hospital. Convenient judgmental sampling 
was used to enroll patients to avoid missing data. Data was retrieved from the hospital 
information system (HIS). Study sample size was 181, calculation based on ovarian cancer 
prevalence in Pakistan, i.e., 13.6 % (13) using 95 % confidence interval and 5 % margin of 
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error. However, more patients were enrolled for improved reliability and statistical power. 
Enrolled OC patients were segregated into 7 chemo-arms, i.e., paclitaxel (PTX), topotecan 
(TOPO), carboplatin + liposomal doxorubicin (CLD), carboplatin + gemcitabine (CG), car-
boplatin + paclitaxel (CP), carboplatin + docetaxel (CD), carboplatin + gemcitabine + beva-
cizumab (CGB). 
All ovarian cancer patients with conformed diagnosis as per the International Fede-
ration of Gynecology and Obstetrics (FIGO) staging system (Table SI) and conforming 
 inclusion/exclusion criteria were included in the study.
Inclusion criteria. – All recurrent OC patients, above 18 years of age, irrespective of 
religion, race and ethnicity, disease stage, with normal hepatic and renal functions, who 
had given consent for their participation in research studies were included in the study.
Exclusion criteria. – Women below 18 years of age having compromised renal and he-
patic functions, incomplete chemotherapy cycles and who failed to provide informed con-
sent were excluded from the study.
Data collection
A data collection form was designed to fulfill all the necessary objectives of the study. 
Clinical data included patients’ basic demographics, histology subtype and FIGO staging, 
details of chemotherapeutic protocols, patient non-compliance due to interruptions or tox-
icity, therapy responses and relevant laboratory findings. All treatment plans, dose, fre-
quency and cycles, are summarized in supplementary materials (Table SI).
Outcome measures
Primary end points of the study were progression-free survival (PFS) and rate of over-
all survival (OS) (14). Clinical response was evaluated both by the tumor marker CA-125 
levels and radiological examination using new response evaluation criteria in solid tumor 
(RECIST) guidelines (supplementary material, Table SII) (15). Laboratory values were as-
sessed at a baseline and after every chemotherapy cycle. Adverse events were graded ac-
cording to the NCI common terminology criteria for adverse events (NCI-CTCAE), version 
3.0 (16). Patient compliance was assessed by treatment interruptions and delays due to 
disease progression, death and toxicity.
Data analysis
All statistical analyses were performed using Graphpad (Prism5) and SPSS (IBM, ver-
sion 21). PFS and OS curves were estimated by the Kaplan-Meier method and compared 
using a log-rank test (17). Frequency of untoward events/deaths during chemotherapy was 
determined by the Cox proportional hazard model for PFS and OS (18). Laboratory mean 
values in all the chemotherapy protocols were compared by the analysis of variance (ANO-
VA). p-value of 0.05 or less was considered statistically significant. 
RESULTS AND DISCUSSION
Clinical characteristics of OC patients are summarized in Table I. The median age ranged 
from 48.5–55 years in all therapeutic arms (Table I). Surprisingly, compared to our findings 
90
S. Sattar et al.: Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different 
chemo-protocols, Acta Pharm. 69 (2019) 87–97.
 
of the early age (median 48 years) reporting of recurrent OC in women of Lahore, Pakistan, 
the reporting age of women was usually above 55 years in Europe and US (18, 19). It is also 
plausible that young women of Lahore, Pakistan, are exposed to specific or increased risks 
earlier in their life for an unascertained period of time of known or unknown origin. Irre-
spective of chemo-protocols, stage IIIC was the most frequently reported FIGO stage with 
the following frequency distribution within the respective arms, i.e., paclitaxel (PTX): 64.2 
%, topotecan (TOPO): 42.4 %, carboplatin + liposomal doxorubicin (CLD): 42.8 %, carbopla-
tin + gemcitabine (CG): 66.6 %, carboplatin + paclitaxel (CP): 52.2 %, carboplatin + docetaxel 
(CD): 53.3 % and carboplatin + gemcitabine + bivacizumab (CGB): 60.3 %, followed by stage 
IV (Table I). Likewise, papillary serous was the most common histological stage (PTX: 27.2 
%, TOPO: 39.3 %, CLD: 24.0 %, CG: 16.6 %, CP: 16.7 %, CD: 13.3 % and CGB: 30.0 %), fol-
lowed by poorly differentiated histology (Table I). The above mentioned findings corrobo-
rate many other reports (20, 21), suggesting that irrespective of ethnicity and geographical 
region, ovarian cancer clinical presentations exhibit minimal differences.
Lately, with the introduction of paclitaxel (21), carboplatin plus paclitaxel has become 
the standard combination therapy in advanced and recurrent ovarian cancer (platinum 
sensitive) (22, 23). In a systematic review, Fung-Kee-Fung et al. (24) found that in five out of 
thirteen trials almost all patients were platinum sensitive and re-treatment with platinum 
based combination significantly improved PFS and OS. Combination of a platinum based 
drug with either paclitaxel or gemcitabine has been shown to improve the response rate in 
Fig. 1. Kaplan-Meier survival curves for all seven protocols: a) progression-free survival (PFS) curves 
for all seven chemo-protocols compared by the log-rank test. Death reported during the period of 
therapy was considered an event, b) overall survival curves for all seven protocols compared by the 
log-rank test.
a)                                                                            b)
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IA 0 0 1 (5) 2 (3) 5 (5) 0 0
IB 0 0 1 (5) 2 (3) 0 2 (13) 0
IC 1 (5) 1 (3) 0 2 (3) 7 (8) 0 0
IIA 0 0 1 (5) 1 (2) 6 (5) 1 (7) 1 (10)
IIB 0 0 1 (5) 2 (3) 7 (8) 0 0
IIIA 0 1 (3) 2 (10) 0 1 (1) 1 (7) 0
IIIB 1 (5) 0 1 (5) 1 (2) 2 (2) 1 (7) 0
IIIC 14 (64) 14 (42) 9 (42) 40 (67) 47 (52) 8 (53) 6 (60)
IV 6 (27) 13 (40) 5 (23) 10 (17) 15 (17) 2 (13) 3 (30)
Missing    0 4 (12) 0 0 0 0 0
Histo-pathology
Endometrioid 2 (9) 1 (3) 3 (14) 11 (18) 17 (18) 2 (13) 0
Poorly differentiated 7 (32) 7 (21) 5 (24) 7 (12) 19 (21) 2 (13) 2 (20)
Serous 1 (4) 2 (6) 2 (9) 7 (12) 11 (12) 2 (13) 3 (30)
Papillary serous 6 (27) 13 (39) 7 (33) 15 (25) 19 (21) 5 (33) 2 (20)
High grade serous 3 (14) 1 (3) 1 (5) 11 (18) 5 (6) 3 (20) 3 (30)
Mucinous 0 4 (12) 0 0 5 (6) 1 (7) 0
Clear cell 2 (9) 3 (9) 1 (5) 4 (7) 6 (7) 0 0
Missing 1 (4) 2 (6) 2 (9) 5 (8) 8 (9) 0 0
FIGO – International Federation of Gynecology and Obstetrics
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patients with recurrent ovarian cancer (9, 22). In our study, clinical response to chemo-
therapy protocols was assessed according to RECIST (supplementary material, Table SII). 
After the 3rd cycle, partial response (PR) was observed in 62 % patients belonging to CP 
and CGB arms while it was ~50 % in paclitaxel, CLD and CG arms (Table II). After the 3rd 
cycle, stable disease (SD) frequency was observed in 40 % patients in CD, 28.5 % in CLD 
and 22.7 % in the paclitaxel arm. After the 6th cycle, CR frequency improved slightly in all 
the treatment arms – more markedly in the CP (52 %) arm, but with reduced PR (Table II). 
Progressive disease (PD) frequency increased markedly in paclitaxel (27 %), topotecan (57 
%), CLD (23.8 %) and CG (31.7 %) arms (Table II). More recently, the CD combination has 
been employed in platinum sensitive recurrent ovarian cancer with the overall response 
rate of 70 %, CR of 28 % and median PFS of 12.4 months (25) – complemented by another 
report with CR of 38 % employing CD regimen (26), but with hematological toxicities, i.e., 
neutropenia. In our data, after the 6th cycle, compared to the CP arm (CR, 52 %), the CD 
arm demonstrated CR in 20 % of patients, but also with higher hematological toxicities. 
Similarly to our findings with 52 % complete response (CR) in the CP arm, Gibson et al. (27) 
found CR of 40–60 % in patients on CP regimen. 





























































































































Response to chemotherapy: n (%)
After 3 cycles
PR 11 (50) 10 (30) 11 (52) 31 (52) 57 (63) 5 (33) 8 (80)
CR 1 (4) – 1 (5) 2 (3) 16 (18) – –
SD 5 (23) 6 (18) 6 (29) 11 (18) 11 (12) 6 (41) 2 (20)
PD 4 (18) 12 (36) 3 (14) 7 (12) 2 (3) 2 (13) –
Missing 1 (4) 5 (15) – 9 (15) 4 (4) 2 (13) –
After 6 cycles
PR 8 (36) 6 (18) 6 (28) 19 (31) 19 (21) 4 (27) 3 (30)
CR 3 (13) 1 (3) 3 (14) 4 (7) 47 (52) 3 (20) 1 (10)
SD 2 (9) 4 (12) 4 (19) 12 (20) 10 (11) 3 (20) 5 (50)
PD 6 (27) 19 (57) 5 (24) 19 (32) 11 (12) 3 (20) 1 (10)
Missing 3 (14) 3 (9) 3 (14) 6 (10) 3 (3) 2 (13) –
CR – complete response, PD – progressive disease, PR – partial response, RECIST – response evaluation criteria in 
solid tumors, SD – stable disease
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As shown in Fig. 1, no significant differences were observed between patients’ sur-
vival PFS (log-rank test, p = 0.12) and OS (log-rank test, p = 0.22) on various chemo-protocols 
(Fig. 1). The highest median progression-free survival (PFS) was observed in the CP arm 
(15 months) followed by CGB (13 months), CD (11.5 months), CLD (9 months), CG (8 
months), PTX (7.5 months) and TOPO (5 months) arms. Nevertheless, the median overall 
survival was highest in the CD arm (21 months) and lowest in the CG arm (8 months). 
Similarly to our findings, the ICON4/OVAR2.2 trial demonstrated that addition of pacli-
taxel to carboplatin extended the PFS and OS in ovarian cancer patients (28). However, 
when we compared PFS and OS in CP and CG arms, no significant differences were ob-
served; yet, the maximum non-compliance frequency was observed in the CG (81.6 %) arm, 
presumably due to grade 1–3 hematological toxicities. Likewise, the AGO-OVAR-led inter-
group trial in recurrent ovarian cancer patients compared CG with CP regimens, demon-
strating similar PFS with no improvement in OS, but with treatment delays that were at-
tributed to myelo-suppression (29). Other studies reported that CLD was as efficacious as 
CP (20, 30); however, in the MITO-2 trial, despite no improvements in PFS and OS, pe-
gylated liposomal doxorubicin (PLD) plus carboplatin was suggested as an alternative first 
line chemo regimen comparable to the CP regimen (19) taking into account the toxicity 
profiles and observed confidence intervals.
Table III. Patient compliance for various chemotherapy protocols



































































































































Cause of treatment interruption (n, %)
Missing 
information – – – – 3 (3) 1 (7) 1 (10)
Progression/
death 3 (14) 14 (42) 3 (14) 10 (16) 5 (6) 3 (20) –
Toxicity 1 (4) 2 (6) 4 (19) 37 (62) 29 (32) 7 (46) 6 (60)
Others 0 6 (18) 7 (20) 12 (20) – 2 (13) 1 (10)
Toxicity delays
2nd cycle 0 0 1 20 4 2 2
3rd cycle 0 1 2 5 6 2 3
4th cycle 0 1 0 3 5 1 0
5th cycle 1 0 1 6 9 0 1

















Percent of non-compliance was estimated based on toxicity delays in each cycle and any other reason of interrup-
tion (not reporting to clinic) in treatment without taking into account reported death.
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As for therapy compliance, the proportion of treatment delays due to disease progres-
sion/deaths was highest in topotecan (42.4 %), while due to toxicity, it was highest in the 
carboplatin + gemcitabine arm (61.6 %) (Table III). In the combination regimen, the highest 
treatment non-compliance was observed in the carboplatin + gemcitabine arm (81.6 %), 
while the CP arm exhibited the lowest non-compliance frequency (32.2 %) (Table III). Thus, 
we observed better compliance in mono therapy (paclitaxel: 4.54 %, topotecan: 24.2 %) 
compared to combination therapy; nevertheless, no single therapy (topotecan or paclitaxel) 
exhibited clinical edge over the combination therapy, but there were subtle differences in 
treatment-related adverse events. However, toxicity with topotecan is subject to several 
factors, such as dose schedule adjustments based on the patient’s prior treatment, radiation 
therapy, extent of cumulative myelo-suppression with prior agents (31). More recently, 
bevacizumab has been used in combination with other chemotherapeutic agents in recur-
rent ovarian cancer (32) with improved tolerability and encouraging efficacy. In the 
OCEANS trial, PFS was improved in the CGB arm compared to CG arm with high grade 
hypertension in the bevacizumab arm, duly supported by our findings of grade 2 hyper-
tension in 30 % subjects belonging to the CGB arm (17).
In the multivariate analysis for PFS and OS, only topotecan was significantly associ-
ated with higher rate of events [for PFS: Cox proportional hazard ratio (HR) was 20.22, 
confidence interval (CI) 2.16–188.94, p = 0.008, for OS: HR was 3.83; CI 1.804–8.119, p = 0.0005) 
(Table IV)]. Notably, significant differences were observed in laboratory values among 
Table IV. Cox proportional hazard model for PFS and OS
Factor N Hazard ratio 95 % CI p-value
Protocols Cox proportional hazard model for progression free survival (PFS)
Carboplatin + paclitaxel 90 Reference
Paclitaxel 22 – – –
Topotecan 33 20.2 (2.16–188.94) 0.008*
Carboplatin + liposomal doxorubicin 21 5.8 (0.36–93.99) 0.21
Carboplatin + gemcitabine 60 8.1 (0.72–89.54) 0.08
Carboplatin + docetaxel 15 6.3 (0.64–62.07) 0.11
Carboplatin + gemcitabine + bevacizumab 10 – – –
Protocols Cox proportional hazard model for overall survival (OS)
Carboplatin + paclitaxel 90 Reference
Paclitaxel 22 0.9 (0.33–2.86) 0.96
Topotecan 33 3.8 (1.80–8.11) 0.0005**
Carboplatin + liposomal doxorubicin 21 1.3 (0.44–3.88) 0.61
Carboplatin + gemcitabine 60 1.3 (0.54–3.40) 0.51
Carboplatin + docetaxel 15 1.3 (0.60–3.25) 0.43
Carboplatin + gemcitabine + bevacizumab 10 0.9 (0.12–7.22) 0.96
*p ≤ 0.05, **p ≤ 0.001 
(–) – no output recorded/obtained in the model.
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various chemo-protocols, such as platelets, neutrophils, hemoglobin, albumin, AST and 
ALT (p < 0.025) (supplementary material, Table SIII). Very few grade-4 toxicities, hemato-
logical and hepatic, were observed in paclitaxel, CG and CP treatment arms (supplemen-
tary material, Table SIV).
CONCLUSIONS
In conclusion, our data suggest that CP chemo-protocol demonstrated better median 
PFS and OS in recurrent ovarian cancer patients, yet statistically non-significant, along 
with maximum partial and complete responses after the 3rd and 6th cycles, resp. In the 
combination regimen, CP was associated with the lowest non-compliance, while the high-
est non-compliance was observed in the CG arm. However, the CP arm was associated 
with considerable hematological and abdominal adverse effects in addition to peripheral 
neuropathy and fatigue. Topotecan was associated with significantly higher propensity of 
having therapy related events/deaths.
Acknowledgements. – The authors are grateful to the hospital administration and patients for 
their kind cooperation and informed consent, helpful in completing the study. Supplementary mate-
rials are available upon request.
REFERENCES
 1.  B. M. Reid, J. B. Permuth and T. A. Sellers, Epidemiology of ovarian cancer: a review, Cancer Biol. 
Med. 14 (2017) 9–32; https://doi.org/10.20892/j.issn.2095-3941.2016.0084
 2.  J. Permuth-Wey and T. A. Sellers, 20. Epidemiology of Ovarian Cancer, in Cancer Epidemiology: Modi-
fiable Factors (Ed. M. Verma)/Series: Methods of Molecular Biology 472 (2009) 413–437, Springer, New 
York 2009; https://doi.org/10.1007/978-1-60327-492-0_20
 3.  J. Ledermann, F. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo and C. Sessa (ESMO 
guidelines working group), Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical 
Practice Guidelines for Diagnosis, Treatment and Follow-up, Ann. Oncol. 24 (Suppl. 6) (2013) vi24-vi32. 
https://doi.org/10.1093/annonc/mdt333
 4.  F. Raja, N. Chopra and J. Ledermann, Optimal first-line treatment in ovarian cancer, Ann. Oncol. 
23 (Suppl. 10) (2012) x118-x127; https://doi.org/10.1093/annonc/mds315
 5.  M. Cristea, E. Han, L. Salmon and R. J. Morgan, Review: Practical considerations in ovarian cancer 
chemotherapy, Ther. Adv. Med. Oncol. 2 (2010) 175–187; https://doi.org/10.1177/1758834010361333
 6.  M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidi and J. P. Ioannidis, Survival benefits with di-
verse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. 
Cancer Inst. 98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj443
 7.  M. A. Bookman (Ed.), GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and 
carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topo-
tecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal 
(PPC) carcinoma, J. Clin. Oncol. 24 (Suppl.) (2006) 5002–5002 (ASCO Annual Meeting Proceedings 
2006); https://doi.org/10.1200/jco.2006.24.18_suppl.5002
 8.  J. A. Ledermann and R. S. Kristeleit, Optimal treatment for relapsing ovarian cancer, Ann. Oncol. 
21 (Suppl. 7) (2010) vii218-222; https://doi.org/10.1093/annonc/mdq377
 9.  D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. E. Hummer. D. R. Venka-
traman and R. Spriggs, Retrospective analysis of carboplatin and paclitaxel as initial second-line 
96
S. Sattar et al.: Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different 
chemo-protocols, Acta Pharm. 69 (2019) 87–97.
 
therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state 
model of ovarian cancer, J. Clin. Oncol. 20 (2002) 1238–1247; https://doi.org/ 10.1200/
JCO.2002.20.5.1238
10.  M. U. Rashid, A. Zaidi, D. Torres, F. Sultan, A. Benner, B. Naqvi, A. R. Shakoori, A. Seidel-Ren-
kert, H. Farooq, S. Narod, A. Amin and U. Hamann, Prevalence of BRCA1 and BRCA2 mutations 
in Pakistani breast and ovarian cancer patients, Int. J. Cancer 119 (2006) 2832–2839; https://doi.
org/10.1002/ijc.22269
11.  M. A. Moore, Y. Ariyaratne, F. Badar, Y. Bhurgri, K. Datta, A. Mathew, P. Gangadharan, A. Nan-
dakumar, K. K. Pradhananga, M. H. Talukder, B. B. Yeole and T. Sobue, Cancer epidemiology in 
South Asia - past, present and future, Asian Pac. J. Cancer Prev. 11 (Suppl. 2) (2010) 49–66.
12.  Y. Bhurgri, Karachi cancer registry data - implications for the National Cancer Control Program 
of Pakistan, Asian Pac. J. Cancer Prev. 5 (2004) 77–82.
13.  Ovarian cancer second most common type in Pakistan, The Daily News 2016, https://www.the-
news.com.pk/print/105779-Ovarian-cancer-second-most-common-type-in Pakistan; last access 
date July 15, 2018.
14.  P. Cheema and R. Burkes, Overall survival should be the primary endpoint in clinical trials for 
advanced non-small-cell lung cancer, Curr. Oncol. 20 (2013) e150; https://doi.org/10.3747/co.20.1226
15.  E. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. 
Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, 
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. 
Cancer 45 (2009) 228–247; https://doi.org/10.1016/j.ejca.2008.10.026
16.  S. Zhang, F. Liang and I. Tannock, Use and misuse of common terminology criteria for adverse 
events in cancer clinical trials, BMC Cancer 16 (2016) Article ID 392 (6 pages); https://doi.org/10.1186/
s12885-016-2408-9
17.  C. Aghajanian, S. V. Blank, B. A. Goff, P. L. Judson, M. G. Teneriello, A. Husain, M. A. Sovak, J. Yi 
and L. R. Nycum, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of 
chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epi-
thelial ovarian, primary peritoneal, or fallopian tube cancer, J. Clin. Oncol. 30 (2012) 2039–2045; 
https://doi.org/10.1200/JCO.2012.42.0505
18.  M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis and J. P. Ioannidis, Survival benefits with 
diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. 
Cancer Inst. 98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj443
19.  S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, P. Musso, L. 
Frigerio, P. Del Medico, A. V. Lombardi, A. Febbraro, P. Scollo, A. Ferro, S. Tamberi, A. Brandes, A. 
Ravaioli, M. R. Valerio, E. Aitini, D. Natale, L. Scaltriti, S. Greggi, C. Pisano, D. Lorusso, V. Salu-
tari, F. Legge, M. Di Maio, A. Morabito, C. Gallo and F. Perrone, Carboplatin plus paclitaxel versus 
carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian 
cancer: the MITO-2 randomized phase III trial, J. Clin. Oncol. 29 (2011) 3628–3635; https://doi.org/ 
10.1200/JCO.2010.33.8566
20.  R. S. Suidan, C. M. St Clair, S. J. Lee, J. N. Barlin, K. C. Long Roche, E. J. Tanner, Y. Sonoda, R. R. 
Barakat, O. Zivanovic and D. S. Chi, A comparison of primary intraperitoneal chemotherapy to 
consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer, Gy-
necol. Oncol. 134 (2014) 468–472; https://doi.org/10.1016/j.ygyno.2014.07.090
21.  M. J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. 
Vergote, R. B. R. Grimshaw, R. J. Atkinson, K. D. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tu-
molo, P. Timmers, J. Roy, F. Lhoas, B. Lindvall, M. Bacon, A. Birt, J. E. Andersen, B. Zee, J. Paul, B. 
Baron and S. Pecorelli, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin–cyclo-
phosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Can-
cer Inst. 92 (2000) 699–708; https://doi.org/10.1093/jnci/92.9.699
97
S. Sattar et al.: Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different 
chemo-protocols, Acta Pharm. 69 (2019) 87–97.
 
22.  A. du Bois, H. J. Lück, W. Meier, H. P. Adams, V. Möbus, S. Costa, T. Bauknecht, B. Richter, M. 
Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn and J. Pfis-
terer, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line 
treatment of ovarian cancer, J. Natl. Cancer Inst. 95 (2003) 1320–1329; doi 10.1093/jnci/djg036
23.  R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. 
DeGeest, E. M. Hartenbach and R. Baergen, Phase III trial of carboplatin and paclitaxel compared 
with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gyne-
cologic Oncology Group study, J. Clin. Oncol. 21 (2003) 3194–3200; https://doi.org/10.1200/
jco.2003.02.153
24.  M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H. W. Hirte and P. Bryson, Optimal chemotherapy 
treatment for women with recurrent ovarian cancer, Curr. Oncol. 14 (2007) 195–208.
25.  Y. Wang, J. Herrstedt, H. Havsteen, R. DePoint Christensen, M. R. Mirza, B. Lund, J. Maenpaa 
and G. Kristensen, A multicenter, non-randomized, phase II study of docetaxel and carboplatin 
administered every 3 weeks as second line chemotherapy in patients with first relapse of plati-
num sensitive epithelial ovarian, peritoneal or fallopian tube cancer, BMC Cancer 14 (2014) Article 
ID 937 (7 pages); https://doi.org/10.1186/1471-2407-14-937
26.  L. A. Holmberg, P. Paley and B. Goff, Docetaxel and carboplatin as salvage therapy for first-re-
lapsed, platinum-sensitive, stage III/IV advanced ovarian cancer, Clin. Ovar. Other Gynecol. Cancer 
7 (2014) 13–17; https://doi.org/10.1016/j.cogc.2014.12.005
27.  J. M. Gibson, S. Alzghari, C. Ahn, H. Trantham and N. M. La-Beck, The role of pegylated liposo-
mal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials, Oncologist 18 
(2013) 1022–1031; https://doi.org/ 10.1634/theoncologist.2013-0126
28.  M. Parmar, J. Ledermann, N. Colombo, A. du Bois, J. F. Delaloye, G. B. Kristensen, S. Wheeler, A. 
M. Swart, W. Qian, V. Torri, I. Floriani, G. Jayson and A. Lamont, C. Tropé, Paclitaxel plus plati-
num-based chemotherapy versus conventional platinum-based chemotherapy in women with 
relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet 361 (2003) 2099–2106; https://doi.
org/10.1016/S0140-6736(03)13718-X
29.  J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stähle, G. Stu-
art, R. Kimmig, S. Olbricht, T. Le, J. Emerich, W. Kuhn, J. Bentley, C. Jackisch, H. J. Lück, J. Ro-
chon, A. H. Zimmermann and E. Eisenhauer, Gemcitabine plus carboplatin compared with car-
boplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the 
AGO-OVAR, the NCIC CTG, and the EORTC GCG, J. Clin. Oncol. 24 (2006) 4699–4707; https://doi.
org/10.1200/JCO.2006.06.0913
30.  D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H. P. 
Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodou-
lou, P. Papakostas, D. Pectasides and A. M. Dimopoulos, A randomized phase II study of carbo-
platin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensi-
tive ovarian cancer patients: a Hellenic Cooperative Oncology Group study, BMC Med. 8 (2010) 
Article ID 3 (12 pages); https://doi.org/10.1186/1741-7015-8-3 
31.  C. J. Dunton, Management of treatment-related toxicity in advanced ovarian cancer, Oncologist 7 
(Suppl. 5) (2002) 11–19.
32.  K. Kudoh, M. Takano, H. Kouta, R. Kikuchi, T. Kita, M. Miyamoto, A. Watanabe, M. Kato, T. Goto 
and Y. Kikuchi, Effects of bevacizumab and pegylated liposomal doxorubicin for the patients 
with recurrent or refractory ovarian cancers, Gynecol. Oncol. 122 (2011) 233–237; https://doi.
org/10.1016/j.ygyno.2011.04.046
